Thousands more women with breast cancer could benefit from a blockbuster immunotherapy drug than previously thought, research suggests.
Pembrolizumab, sold under the brand name Keytruda, targets and blocks a specific protein on the surface of certain immune cells that then seek out and destroy the cancerous cells.
